Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement

Oct

29

Today In Oncology

TIL Therapy Plus Pembrolizumab for Advanced Melanoma

Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction

Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer

Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors

Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC

Advertisement

© 2026 HSP News Service, L.L.C.